Semisolid dosage forms are neither solid nor liquid, however, they are a combination or mixture of both, and they used for both local and systemic effects. Pharmaceutical semisolid dosage forms such as creams, ointments, gels, suppositories, and paste are used for topical application. Semisolid dosage forms are intended used as drug carriers that are transported topically through the skin, buckle tissue, rectal tissue, outer ear lining nasal mucosa, urethral membrane, vagina, and cornea. The semisolid may adhere adequately before washing on the surface of the application; this helps to extend the supply of drugs on the application site.
Semisolid dosage forms are neither solid nor liquid, however, they are a combination or mixture of both, and they used for both local and systemic effects. Pharmaceutical semisolid dosage forms such as creams, ointments, gels, suppositories, and paste are used for topical application. Semisolid dosage forms are intended used as drug carriers that are transported topically through the skin, buckle tissue, rectal tissue, outer ear lining nasal mucosa, urethral membrane, vagina, and cornea. The semisolid may adhere adequately before washing on the surface of the application; this helps to extend the supply of drugs on the application site.
SOURCES OF ERROR IN PRESCRIPTION
1. Abbreviation
2. Name of the drug
3. Strength of the preparation
4. Dosage form of the drug prescribed
5. Dose
6. Instructions for the patient
7. Incompatibilities
1. ABBREVIATION
Abbreviation presents a problem in understanding parts of
prescription order.
Extreme care should be taken by a pharmacist in interpreting the
abbreviation.
Pharmacist should not guess at the meaning of an ambiguous
abbreviation.
E.g: Dispense Achromycin for “Achro” may cause difficulty when a
intention of the prescriber is to dispense Achrostatin.
2. NAME OF THE DRUG
There are certain drugs whose name look or sound like those of
other drugs.
E.g: Digitoxin Digoxin
Prednisone Prednisolone
3. STRENGTH OF THE PREPARATION
The strength of preparation should be stated by prescriber.
It is essential when various strengths of a product are available in
the market.
E.g: It will be a wrong decision on the part of pharmacist to
dispense paracetamol tablet 500 mg when prescription for
paracetamol tablet is received with no specific strength.
4. DOSAGE FORM OF THE DRUG PRESCRIBED
Many medicines are available in more than one dosage form.
E.g: Liquid, Tablet, Capsule and Suppository.
The pharmaceutical form of the product should be written on the
prescription in order to avoid ambiguity.
5. DOSE
Unusually high or low doses should be discussed with the
prescriber.
Paediatric dosage may present a problem. So pharmacist should
consult paediatric posology to avoid any error.
Sometimes a reasonable dose is administered too frequently.
E.g: A prescription for sustained release formulation to be
administered after every 4 hours should thoroughly check
because such dosage forms are usually administered only two or
three times a day.
6. INSTRUCTIONS FOR THE PATIENT
The instructions for the patient which are given in the
prescription are incomplete or omitted.
The quantity of the drug to be taken, the frequently and timing of
administration and route of administration should clearly give in
the prescription so as to avoid confusion.
7. INCOMPATIBILITIES
It is essential to check that there are no pharmaceutical or
therapeutic incompatibilities in a prescribed preparation and
that different medicines prescribed for the same patient do not
interact with each other to produce any harm to the patient.
Certain antibiotics should not be given with meals since it
significantly decrease the absorption of the drug.
In this presentation viewers will able to learn about liquids for external use such as liniments and lotions, liquids for oral cavity such as mouthwash, throat paints and gargles.
it is GTU based syllabus chapter and all the points are covered like... handling of prescription , etc... very helpful for pharmacy students...and its in easy language..
Semisolid dosage forms: Definitions, classification, mechanisms and factors influencing dermal penetration of drugs. Preparation of ointments, pastes, creams and gels. Excipients used in semi solid dosage forms. Evaluation of semi solid dosages forms
SOURCES OF ERROR IN PRESCRIPTION
1. Abbreviation
2. Name of the drug
3. Strength of the preparation
4. Dosage form of the drug prescribed
5. Dose
6. Instructions for the patient
7. Incompatibilities
1. ABBREVIATION
Abbreviation presents a problem in understanding parts of
prescription order.
Extreme care should be taken by a pharmacist in interpreting the
abbreviation.
Pharmacist should not guess at the meaning of an ambiguous
abbreviation.
E.g: Dispense Achromycin for “Achro” may cause difficulty when a
intention of the prescriber is to dispense Achrostatin.
2. NAME OF THE DRUG
There are certain drugs whose name look or sound like those of
other drugs.
E.g: Digitoxin Digoxin
Prednisone Prednisolone
3. STRENGTH OF THE PREPARATION
The strength of preparation should be stated by prescriber.
It is essential when various strengths of a product are available in
the market.
E.g: It will be a wrong decision on the part of pharmacist to
dispense paracetamol tablet 500 mg when prescription for
paracetamol tablet is received with no specific strength.
4. DOSAGE FORM OF THE DRUG PRESCRIBED
Many medicines are available in more than one dosage form.
E.g: Liquid, Tablet, Capsule and Suppository.
The pharmaceutical form of the product should be written on the
prescription in order to avoid ambiguity.
5. DOSE
Unusually high or low doses should be discussed with the
prescriber.
Paediatric dosage may present a problem. So pharmacist should
consult paediatric posology to avoid any error.
Sometimes a reasonable dose is administered too frequently.
E.g: A prescription for sustained release formulation to be
administered after every 4 hours should thoroughly check
because such dosage forms are usually administered only two or
three times a day.
6. INSTRUCTIONS FOR THE PATIENT
The instructions for the patient which are given in the
prescription are incomplete or omitted.
The quantity of the drug to be taken, the frequently and timing of
administration and route of administration should clearly give in
the prescription so as to avoid confusion.
7. INCOMPATIBILITIES
It is essential to check that there are no pharmaceutical or
therapeutic incompatibilities in a prescribed preparation and
that different medicines prescribed for the same patient do not
interact with each other to produce any harm to the patient.
Certain antibiotics should not be given with meals since it
significantly decrease the absorption of the drug.
In this presentation viewers will able to learn about liquids for external use such as liniments and lotions, liquids for oral cavity such as mouthwash, throat paints and gargles.
it is GTU based syllabus chapter and all the points are covered like... handling of prescription , etc... very helpful for pharmacy students...and its in easy language..
Semisolid dosage forms: Definitions, classification, mechanisms and factors influencing dermal penetration of drugs. Preparation of ointments, pastes, creams and gels. Excipients used in semi solid dosage forms. Evaluation of semi solid dosages forms
posology is a branch of medical science which deals with dose or quantity of drugs which can be administered to a patient to get the desired pharmacological actions.
This ppt covers definition of Posology, Therapeutic dose, Official doses, factors deciding dose calculation, and formulae used for child dose calculation.
It is useful for medical and pharmacy students
Before prescribing any pharmaceutical medicine, the physician should consider certain factors that can modify the effect of the drug. The same dose of a drug can produce different degrees of response in different patients and even in the same patient under different situations. The Important factors modify the effect of a drug are subdivided into two groups: patient related factors and drug related factors.
• Patient related factors: age, gender, body weight, presence of food, drug allergy, genetic variation, environmental state, pathological state, psychological state, etc.
• Drug related factors: physical state of a drug, route of drug administration, time of drug administration, drug cumulation, drug combination, drug tolerance, drug dependence, etc.
Therapeutic Regimen
Dose-response Curve
Drug Toxicity
Symptoms, Diagnosis & Treatment Of Drug Toxicity
Dosage Regimen
Factors To Consider In Design Of Drug Dosage Regimens
Methods To Design A Dosage Regimen
Dosing Of Drugs In Infants And Children
Dosing Of Drugs In The Elderly
Clinical Trial
Planetary mixtures are one of the most widely used mixtures in the pharmaceutical industry. In pharmaceutical industries planetary mixture often used for basic operations of mixing, blending, and low share granulation.
sulfonamides are the antimicrobial agents.It's act by folic acid synthesis inhibitors.It is PABA analogue competitive antagonist. first synthesised drug is prontosil.
In this slide contents history, mechanism of action, SAR, classification of drugs, some structure of important drugs, choice of drugs in different purpose, side effect, adverse effect.
meta analysis of plants used as nootropic agents.
nootropic agents means the chemical which increases the memory and brain energy and balance the conditions of neurochemicals.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
3. Introduction
• Posology: the term derived from the Greek word “Posos” means how much and “Logos”
means science.
• Posology is the branch of medical science which deals with dose or quantity of drugs which
can be administered to a patient to get the desired pharmacological action.
• The dose of a drug cannot be fixed rigidly because there are so many factor which influence
the doses.
• The official doses represent the average range of quantities suitable for the adults which
administered orally within 24 hours. When other routes of administration are followed the
relevant appropriate dose given.
• Responsibility of a pharmacist to calculate the appropriate dose each and every patients to
satisfy himself that the overdose has not be prescribed.
4. Factors Influencing Dose
• Age: The pharmacokinetics of many drugs changes with age . So, the age of a patients has
great significance.
• Children and old people need laser amount of drug than normal adult dose, because they
are unable to excrete drugs to that extent adults.
• Sex: Woman do not always respond to the action of drug in the same manner as it is done
in men.
• Morphine and barbiturates may produce more excitement before sedation in woman.
• During lactation antihistamines like morphine and tetracycline drugs are restricted.
5. Factors Influencing Dose
• Body weight: Average adult does is mentioned either in terms of mg/kg body weight or
as a single does for and adult weighing between 50- 100 kg.
• However, the dose is not applicable for children and malnourished patients.
• Route of administration: IV does is lesser than Oral dose. Because, the drugs administered
directly into the systemic circulation.
• For immediate action and special case Intravenous drugs are given.
• Time of administration: the presence of food in stomach delays the absorption of drugs,
while drugs are rapidly absorbed in empty stomach.
• The irritating drugs are better tolerated if administered after meals. E.g: Iron tablets.
6. Factors Influencing Dose
•Environmental factor: Daylight is stimulant, enhancing the effect of stimulating drugs.
Darkness is sedative, hypnotics are shows more effect at night.
•Emotional factor: The personality and behaviour of a physician may influence the effect of
drug especially the drug which are intended for use in psychosomatic disorder.
•Presence of disease: Drugs like barbiturates and chlorpromazine may produce unusually
prolong effect in case of liver cirrhosis patients.
•During fever a patient can tolerate high does antipyretics than a normal person.
7. Factors Influencing Dose
• Accumulation: The drug which are slowly excreted may built up a sufficient high
concentration in the body and produce toxic symptoms if it is repeatedly administered for a
long time.
• Additive effect: When the total pharmacological action of two or more drug administered
together is equivalent to sum of there individual pharmacological action.
• Synergism: When two or more drugs are used in the combination form, and their action is
increased.
• Antagonism: When the action of one drug is opposed by other drug on the same
physiological system is known as antagonism.
8. Factors Influencing Dose
• Idiosyncrasy: An extraordinary response to a drug which is different from its characteristic
pharmacological action is called idiosyncrasy.
• Tolerance: when an unusual large does of a drug is required to elicit an affect ordinarily
produced by the normal therapeutic dose of the drug the phenomenon is termed as drug
tolerance.
• Tachyphylaxis: it has been observed that when certain drugs are administrated repeatedly
at short intervals, the cell receptor get blocked and pharmacological response to that
particular drug is decreased. This phenomenon is called tachyphylaxis/ acute tolerance.
• Metabolic disorder: changes in water electrolyte balance and body temperature and other
physiological factor may modify the effect of drug.
9. Calculations of does
• Doses calculated based on age:
Age in year
Young’s formula: × Adult dose
Age in year + 12.
Age in year
Dilling’s formula: × Adult dose
20
Age (month)
Fried’s formula: × Adult dose
150
10. • Doses calculated based on body weight (Clark’s formula):
Child weight(lb)
× Adult dose
150
Child weight(kg)
× Adult dose
70
• Doses calculated based on surface area:
Child body surface area
× Adult dose (average adult’s body surface area= 1.73m2)
Average adults body surface area
11. Questionnaires
•What is posology?
•What are the different factors which influence the dose?
•Why the quantity of drug which is given by intravenous route is less than oral route.
•Write short notes on: idiosyncrasy, tolerance, tachyphylaxis, additive effect, antagonism.
•Using Young’s rule, calculate the dose for a 5 year old child if the adult dose is 340 mg.
•Using Dilling's rule, calculate the dose for a 10 year old child if the adult dose is 500 mg.
•Using Fried’s rule, calculate the dose for 5 month old child if the adult dose is 600 mg.
•Calculate the does for a child weighing 75 lbs if the adult dose is 300 mg.
•Calculate the does for a child weighing 12 kg if the adult dose is 700 mg.
•Calculate the does for a child whose body surface area is 0.43 m2 if the adult dose is 500 mg.